Recro Pharma Inc (REPH.OQ)
REPH.OQ on NASDAQ Stock Exchange Capital Market
11.70USD
23 Apr 2018
11.70USD
23 Apr 2018
Change (% chg)
$0.21 (+1.83%)
$0.21 (+1.83%)
Prev Close
$11.49
$11.49
Open
$11.49
$11.49
Day's High
$11.76
$11.76
Day's Low
$11.34
$11.34
Volume
28,567
28,567
Avg. Vol
50,657
50,657
52-wk High
$12.20
$12.20
52-wk Low
$5.85
$5.85
Revenue & Earnings Per Share
Revenue* | Earnings Per Share** | ||
---|---|---|---|
FY 2017 | Dec '17 | 19.04 | -0.846 |
Sep '17 | 17.11 | -0.475 | |
Jun '17 | 16.93 | -0.465 | |
Mar '17 | 18.74 | -0.425 | |
FY 2016 | Dec '16 | 17.36 | -0.782 |
Sep '16 | 16.95 | -0.499 | |
Jun '16 | 17.28 | -0.826 | |
Mar '16 | 17.74 | -0.707 |
*Note: Units in Millions ofU.S. Dollars
**Note: Units in U.S. Dollars
Consensus Estimates Analysis
# of Estimates | Mean | High | Low | 1 Year Ago | |
---|---|---|---|---|---|
SALES (in millions) | |||||
Quarter Ending Jun-18 | 4 | 17.21 | 17.80 | 16.50 | 14.99 |
Quarter Ending Sep-18 | 4 | 18.03 | 18.30 | 17.80 | 14.97 |
Year Ending Dec-18 | 4 | 74.00 | 77.60 | 72.00 | 68.96 |
Year Ending Dec-19 | 5 | 110.82 | 121.80 | 102.50 | 109.54 |
Earnings (per share) | |||||
Quarter Ending Jun-18 | 4 | -0.99 | -0.56 | -1.51 | -0.51 |
Quarter Ending Sep-18 | 4 | -0.73 | -0.56 | -0.79 | -0.35 |
Year Ending Dec-18 | 4 | -3.15 | -2.43 | -4.10 | -2.77 |
Year Ending Dec-19 | 5 | -1.47 | -0.83 | -2.43 | -0.93 |
Sales and Profit Figures in US Dollar (USD);
Valuation Ratios
Company | industry | sector | ||
---|---|---|---|---|
P/E Ratio (TTM) | -- | 185.04 | 32.78 | |
P/E High - Last 5 Yrs. | 25.96 | 284.68 | 45.94 | |
P/E Low - Last 5 Yrs. | 25.96 | 95.75 | 24.95 | |
Beta | -0.75 | 0.75 | 0.80 | |
Price to Sales (TTM) | 3.10 | 136.40 | 7.08 | |
Price to Book (MRQ) | 7.75 | 19.34 | 5.00 | |
Price to Tangible Book (MRQ) | -- | 24.06 | 6.75 | |
Price to Cash Flow (TTM) | -- | 122.96 | 25.60 | |
% Owned Institutions | 69.04 | 11.18 | 2.21 |
Dividends
Company | industry | sector | ||
---|---|---|---|---|
Dividend Yield | -- | 0.29 | 1.55 | |
Dividend Yield - 5 Year Avg | -- | 0.20 | 0.74 | |
Dividend 5 Year Growth Rate | -- | 1.94 | 3.92 | |
Payout Ratio(TTM) | -- | 9.18 | 20.28 |
Growth Rates
Company | industry | sector | ||
---|---|---|---|---|
Sales (MRQ) vs Qtr. 1 Yr. Ago | 9.68 | 103.99 | 9.00 | |
Sales (TTM) vs TTM 1 Yr. Ago | 3.60 | 80.63 | 10.85 | |
Sales - 5 Yr. Growth Rate | -- | 33.87 | 8.21 | |
EPS (MRQ) vs Qtr. 1 Yr. Ago | -8.20 | -66.82 | 22.25 | |
EPS (TTM) vs TTM 1 Yr. Ago | 21.44 | -- | -- | |
EPS - 5 Yr. Growth Rate | -- | 47.44 | 10.24 | |
Capital Spending - 5 Yr. Growth Rate | -- | 45.48 | 10.39 |
Financial Strength
Company | industry | sector | |
---|---|---|---|
Quick Ratio (MRQ) | 1.55 | 1.63 | 2.53 |
Current Ratio (MRQ) | 1.75 | 5.97 | 3.62 |
LT Debt to Equity (MRQ) | 185.79 | 23.32 | 11.28 |
Total Debt to Equity (MRQ) | 185.79 | 25.75 | 13.94 |
Interest Coverage (TTM) | -4.65 | -181.71 | 30.08 |
Profitability Ratios
Company | industry | sector | ||
---|---|---|---|---|
Gross Margin (TTM) | 46.83 | 36.28 | 53.98 | |
Gross Margin - 5 Yr. Avg. | -- | 55.36 | 52.10 | |
EBITD Margin (TTM) | -45.75 | -- | -- | |
EBITD - 5 Yr. Avg | -33.65 | -149.35 | 15.94 | |
Operating Margin (TTM) | -56.12 | -564.83 | 4.32 | |
Operating Margin - 5 Yr. Avg. | -44.54 | -161.27 | 11.31 | |
Pre-Tax Margin (TTM) | -72.33 | -537.64 | 4.97 | |
Pre-Tax Margin - 5 Yr. Avg. | -58.97 | -168.32 | 11.62 | |
Net Profit Margin (TTM) | -58.72 | -526.60 | 1.58 | |
Net Profit Margin - 5 Yr. Avg. | -45.28 | -168.70 | 7.94 | |
Effective Tax Rate (TTM) | -- | -0.44 | 31.27 | |
Effective Tax Rate - 5 Yr. Avg. | -- | 18.13 | 24.27 |
Efficiency
Company | industry | sector | ||
---|---|---|---|---|
Revenue/Employee (TTM) | 281,702 | 23,918,133 | 819,537,692 | |
Net Income/Employee (TTM) | -165,412 | 754,796 | 96,346,718 | |
Receivable Turnover (TTM) | 7.15 | 6.24 | 5.57 | |
Inventory Turnover (TTM) | 4.11 | 2.37 | 3.45 | |
Asset Turnover (TTM) | 0.39 | 0.40 | 0.89 |
Management Effectiveness
Company | industry | sector | ||
---|---|---|---|---|
Return on Assets (TTM) | -22.85 | -0.77 | 10.55 | |
Return on Assets - 5 Yr. Avg. | -20.05 | 0.69 | 11.58 | |
Return on Investment (TTM) | -27.84 | -0.74 | 13.21 | |
Return on Investment - 5 Yr. Avg. | -23.90 | 4.20 | 14.99 | |
Return on Equity (TTM) | -83.97 | -2.80 | 15.01 | |
Return on Equity - 5 Yr. Avg. | -74.56 | -0.05 | 16.27 |
1 Year | 3 Year | 5 Year | |
---|---|---|---|
Sales % | 3.60 | -- | -- |
EPS (TTM) % | 21.49 | -- | -- |
Dividend % | -- | -- | -- |
Note: Units in Millions of US Dollars
Performance for Recro Pharma Inc
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Recro Pharma Inc Reports Year End 2017 Financial Results
- BRIEF-Recro Pharma Estimates Cash And Cash Equivalents About $64 Mln As Of Dec 31
- BRIEF-Recro Pharma - Ryan Lake Promoted To CFO
- BRIEF-Recro Pharma Says Entered Into A Sales Agreement With Cowen And Co
- BRIEF-Recro Pharma secures $100 million credit facility
Institutional Holders
% Shares Owned: | 69.04% |
# of Holders: | 93 |
Total Shares Held: | 13,392,058 |
3 Mo. Net Change: | -1,120,733 |
# New Positions: | 3 |
# Closed Positions: | 3 |
# Increased Positions: | 6 |
# Reduced Positions: | 13 |
# Net Buyers: | -7 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.